Business News • PR NewsWire • Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy

Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy

Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other...

View More : https://www.prnewswire.com:443/news-releases/innovent-announces-the-approval-of-pemazyre-pemigatinib-by-the-nmpa-for-the...

Releted News by prnewswire

Statement by NextEra Energy Resources President and CEO and NextEra Energy Partners President Rebecca Kujawa on agreement between the U.S. Department of Justice and ESI Energy

Invitation to presentation of Mycronic's Q1 2022

Sharing Economy International Inc: $30 million to be raised for investing in naked eye 3D technology

Nur ein Jahr nach Markteinführung: ADO (A DECE OASIS) erzielt repräsentatives Jahr mit Rekord über 0,1 Milliarden RMB (16 Mio. USD) an weltweitem Umsatzvolumen